The United States announced an investigation into Germany's pharmaceutical pricing policies on Thursday, a move that could lead to new tariffs. The probe, conducted under Section 301 trade authorities, examines whether German practices underpay for innovative medicines and create an unfair burden on US commerce.
The investigation escalates transatlantic trade tensions amid an ongoing review of global pricing rules. Section 301 has previously been used to target China's intellectual property practices and digital services taxes, making it a potent tool for addressing perceived trade imbalances.
Washington did not specify a timeline for the investigation, but such probes typically precede potential tariff actions. The US Trade Representative will assess whether German pricing mechanisms systematically disadvantage American drugmakers by limiting reimbursement rates for newer therapies.
If the probe results in tariffs, it could raise costs for German pharmaceutical exports and strain relations with a key European ally. The move also signals a broader US effort to challenge national healthcare pricing models that Washington views as trade barriers.
Industry analysts warn that unilateral tariffs could disrupt drug supply chains and increase prices for patients, though German officials have defended their pricing system as essential for controlling healthcare costs.